Arvinas (ARVN) Stock Price, News & Analysis

Company Overview

Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins. The company has also pursued programs in additional disease areas, including neurological and immunological conditions.

Founded in 2013 by Yale University scientist Craig Crews, a pioneer in targeted protein degradation, Arvinas is headquartered in New Haven, Connecticut. The company collaborates with pharmaceutical partners to advance and commercialize selected programs, including a collaboration with Pfizer related to vepdegestrant. Arvinas is led by President and Chief Executive Officer John Houston and serves global markets through its research, development and strategic partnership activities.

Key Stats

• Today's Range: $7.66 to $8.03
• 50-Day Range: $6.82 to $9.60
• 52-Week Range: $6.74 to $14.51
• Volume: 1.13 million shs
• Average Volume: 705,038 shs
• Market Capitalization: $507.13 million
• P/E Ratio: 78.61
• Dividend Yield: N/A
• Price Target: $15.40
• Consensus Rating: Moderate Buy

Arvinas Stock Analysis - MarketRank™

Arvinas scored higher than 46% of companies evaluated by MarketBeat, and ranked 616th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Arvinas has a consensus price target of $15.40, representing about 95.9% upside from its current price of $7.86.

Amount of Analyst Coverage

Arvinas has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arvinas are expected to decrease in the coming year, from $0.05 to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arvinas is 78.61, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arvinas is 78.61, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.77.

Price to Book Value per Share Ratio

Arvinas has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.35% of the float of Arvinas has been sold short.

Short Interest Ratio / Days to Cover

Arvinas has a short interest ratio ("days to cover") of 8.17.

Change versus previous month

Short interest in Arvinas has recently increased by 3.77%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arvinas does not currently pay a dividend.

Dividend Growth

Arvinas does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.45

News Sentiment

Arvinas has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Arvinas this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Arvinas to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arvinas insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.30% of the stock of Arvinas is held by insiders.

Percentage Held by Institutions

95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARVN
• CIK: 1655759
• Web: www.arvinas.com
• Phone: (203) 535-1456
• Fax: N/A
• Employees: 246
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Arvinas: $15.40
• High Price Target: $21.00
• Low Price Target: $10.00
• Potential Upside/Downside: +95.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.10
• Trailing P/E Ratio: 78.61
• Forward P/E Ratio: 157.20
• P/E Growth: N/A
• Net Income: -$80.80 million
• Net Margins: 2.94%
• Pretax Margin: 3.16%
• Return on Equity: 1.91%
• Return on Assets: 1.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.91
• Quick Ratio: 7.91

Sales & Book Value

• Annual Sales: $262.60 million
• Price / Sales: 1.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.76 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 64,520,000
• Free Float: 59,811,000
• Market Cap: $507.13 million
• Optionable: Optionable
• Beta: 1.80